Literature DB >> 17256936

Origin of diastereoselectivity in the tandem oxy-Cope/Claisen/ene reaction: experimental and theoretical studies of the ring inversion mechanism.

Effiette L O Sauer1, James Hooper, Tom Woo, Louis Barriault.   

Abstract

We report herein a detailed investigation into the reaction mechanism of the oxy-Cope/Claisen/ene reaction. A series of chiral substrates was prepared, subjected to the tandem sequence, and the enantiomeric excess of the final products was evaluated. The observed conservation of enantiomeric excess was taken as evidence that the ring inversion of the intermediary enol ether does not occur. DFT calculations were used to map out the potential energy surface for the reaction and evaluate the relative energies of the ring inversions relative to those of the Claisen and ene reactions. Transition state energies thus obtained were found to support the presence of a high-energy transition state for the ring inversion of B to D provided R(1) not equal H. In addition, the calculations lent further support to the hypothesis that the selectivity of the transannular ene reaction is under Curtin-Hammett control.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17256936     DOI: 10.1021/ja066830f

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  3 in total

1.  Structural determination of NSC 670224, synthesis of analogues and biological evaluation.

Authors:  Nathaniel B Zuckerman; Andrew S Myers; Tiffani K Quan; Walter M Bray; R Scott Lokey; Grant A Hartzog; Joseph P Konopelski
Journal:  ChemMedChem       Date:  2012-02-29       Impact factor: 3.466

2.  Enantioselective catalytic transannular ketone-ene reactions.

Authors:  Naomi S Rajapaksa; Eric N Jacobsen
Journal:  Org Lett       Date:  2013-08-08       Impact factor: 6.005

3.  Catalytic, transannular carbonyl-olefin metathesis reactions.

Authors:  Paul S Riehl; Daniel J Nasrallah; Corinna S Schindler
Journal:  Chem Sci       Date:  2019-09-25       Impact factor: 9.825

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.